Literature DB >> 1468698

The impact of subspecialty training on the management of advanced ovarian cancer.

S M Eisenkop1, N M Spirtos, T W Montag, R H Nalick, H J Wang.   

Abstract

A retrospective study was conducted to determine the influence of subspecialty training in gynecologic oncology as well as several other covariates on the feasibility, operative mortality, and survival benefits of cytoreductive surgery for 263 patients with stages IIIC and IVA epithelial ovarian cancer. Covariates most predictive of an optimal (< or = 1 cm) cytoreductive outcome were the diameter of the largest metastases before cytoreduction (< or = 10 cm vs > 10 cm, P < 0.001) and the specialty training of the physicians present at surgery (gynecologic oncologists vs other, P < 0.001). Age influenced operative mortality most (< 60 vs > or = 60, P < 0.001). Covariates found to most significantly influence survival time include the specialty training of the physicians present at surgery (gynecologic oncologists vs other, P < 0.0001), cytoreductive outcome (complete vs optimal, P = 0.001, optimal vs suboptimal, P < 0.0001), grade of tumor (grade 1 vs grades 2 and 3, P = 0.01), and pelvic disease status (frozen pelvis vs mobile primary tumor, P = 0.03). We conclude that patients with advanced epithelial ovarian cancer should undergo aggressive cytoreductive surgery by gynecologic oncologists, with the objective to remove all macroscopic disease. Subsequent treatment with platinum-based chemotherapy offers the best chance for long-term survival or cure.

Entities:  

Mesh:

Year:  1992        PMID: 1468698     DOI: 10.1016/0090-8258(92)90107-t

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

1.  Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

Authors:  Brian Nolen; Liudmila Velikokhatnaya; Adele Marrangoni; Koen De Geest; Aleksey Lomakin; Robert C Bast; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2010-03-24       Impact factor: 5.482

Review 2.  En bloc pelvic resection of ovarian cancer with rectosigmoid colectomy: a literature review.

Authors:  Myeong-Seon Kim; Joseph J Noh; Yoo-Young Lee
Journal:  Gland Surg       Date:  2021-03

3.  Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma.

Authors:  Mohamed A F Hegazy; Refaat A F Hegazi; Mohamed A Elshafei; Ahmed E Setit; Maged R Elshamy; Mohamed Eltatoongy; Amal A F Halim
Journal:  World J Surg Oncol       Date:  2005-08-31       Impact factor: 2.754

4.  In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.

Authors:  Lele Shashikant; P Kesterson Joshua
Journal:  J Obstet Gynaecol India       Date:  2009 May-Jun

5.  The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

Authors:  Oliver Zivanovic; Camelia S Sima; Alexia Iasonos; William J Hoskins; Pavani R Pingle; Mario M M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2010-03       Impact factor: 5.482

6.  Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Expert Opin Med Diagn       Date:  2012-03

Review 7.  Female Pelvic Medicine and Reconstructive Surgery-What Does Certification Mean?

Authors:  Steven J Weissbart; Alan J Wein; Ariana L Smith
Journal:  Curr Urol Rep       Date:  2018-03-19       Impact factor: 3.092

8.  Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States.

Authors:  Shamly Austin; Michelle Y Martin; Yongin Kim; Ellen M Funkhouser; Edward E Partridge; Maria Pisu
Journal:  Health Serv Res       Date:  2012-12-03       Impact factor: 3.402

9.  Surgical outcomes in women with ovarian cancer.

Authors:  Laurie M Elit; Susan J Bondy; Lawrence P Paszat; Eric J Holowaty; Gillian M Thomas; Therese A Stukel; Mark N Levine
Journal:  Can J Surg       Date:  2008-10       Impact factor: 2.089

10.  Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy.

Authors:  Jean-Luc Brun; Roman Rouzier; Frédéric Selle; Sidney Houry; Serge Uzan; Emile Daraï
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.